JP7792426B2 - 極めて強力なｍ－ｃｅｎｋ細胞及び方法 - Google Patents

極めて強力なｍ－ｃｅｎｋ細胞及び方法

Info

Publication number
JP7792426B2
JP7792426B2 JP2023553498A JP2023553498A JP7792426B2 JP 7792426 B2 JP7792426 B2 JP 7792426B2 JP 2023553498 A JP2023553498 A JP 2023553498A JP 2023553498 A JP2023553498 A JP 2023553498A JP 7792426 B2 JP7792426 B2 JP 7792426B2
Authority
JP
Japan
Prior art keywords
cells
cenk
txm
cell
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023553498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508906A (ja
Inventor
サクセナ，マンジュ
ラザ アリ，サイド
アンダーソン，グレッグ
スン－シオン，パトリック
Original Assignee
イミュニティバイオ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュニティバイオ，インコーポレーテッド filed Critical イミュニティバイオ，インコーポレーテッド
Publication of JP2024508906A publication Critical patent/JP2024508906A/ja
Priority to JP2025135655A priority Critical patent/JP2025186248A/ja
Application granted granted Critical
Publication of JP7792426B2 publication Critical patent/JP7792426B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2023553498A 2021-03-03 2022-03-01 極めて強力なｍ－ｃｅｎｋ細胞及び方法 Active JP7792426B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135655A JP2025186248A (ja) 2021-03-03 2025-08-18 極めて強力なｍ－ｃｅｎｋ細胞及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163156269P 2021-03-03 2021-03-03
US63/156,269 2021-03-03
US202163217097P 2021-06-30 2021-06-30
US63/217,097 2021-06-30
PCT/US2022/018290 WO2022187207A1 (en) 2021-03-03 2022-03-01 Highly potent m-cenk cells and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135655A Division JP2025186248A (ja) 2021-03-03 2025-08-18 極めて強力なｍ－ｃｅｎｋ細胞及び方法

Publications (2)

Publication Number Publication Date
JP2024508906A JP2024508906A (ja) 2024-02-28
JP7792426B2 true JP7792426B2 (ja) 2025-12-25

Family

ID=83154407

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023553498A Active JP7792426B2 (ja) 2021-03-03 2022-03-01 極めて強力なｍ－ｃｅｎｋ細胞及び方法
JP2025135655A Pending JP2025186248A (ja) 2021-03-03 2025-08-18 極めて強力なｍ－ｃｅｎｋ細胞及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135655A Pending JP2025186248A (ja) 2021-03-03 2025-08-18 極めて強力なｍ－ｃｅｎｋ細胞及び方法

Country Status (7)

Country Link
US (1) US20240228964A9 (https=)
EP (1) EP4301846A4 (https=)
JP (2) JP7792426B2 (https=)
KR (1) KR20230137392A (https=)
AU (2) AU2022230374B2 (https=)
CA (1) CA3211456A1 (https=)
WO (1) WO2022187207A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024206936A2 (en) * 2023-03-30 2024-10-03 The Trustees Of The University Of Pennsylvania Interleukin-18 pretreatment as a cryoprotectant for lymphocytes
WO2024205965A1 (en) * 2023-03-31 2024-10-03 Immunitybio, Inc. Il-12/il-18 superkines
WO2026024752A1 (en) 2024-07-23 2026-01-29 Immunitybio, Inc. Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021006876A1 (en) 2019-07-08 2021-01-14 Nantkwest, Inc. Ciml nk cells and methods therefor
WO2021006875A1 (en) 2019-07-08 2021-01-14 Nantkwest, Inc. Mononuclear cell derived nk cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102867975B1 (ko) * 2017-03-06 2025-10-14 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
US20210008107A1 (en) * 2019-07-08 2021-01-14 Nantkwest, Inc. CIML NK cells and Methods Therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021006876A1 (en) 2019-07-08 2021-01-14 Nantkwest, Inc. Ciml nk cells and methods therefor
WO2021006875A1 (en) 2019-07-08 2021-01-14 Nantkwest, Inc. Mononuclear cell derived nk cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Moustaki, A. et al.，Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function，Cancer Immunol Immunother，2011年，vol.60，p.1683-1695
Perez, S. A. et al.，A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival，Blood，2005年，vol.106, no.1，p.158-166

Also Published As

Publication number Publication date
EP4301846A4 (en) 2025-03-05
AU2022230374B2 (en) 2025-06-19
WO2022187207A1 (en) 2022-09-09
AU2022230374A1 (en) 2023-08-17
JP2024508906A (ja) 2024-02-28
EP4301846A1 (en) 2024-01-10
US20240228964A9 (en) 2024-07-11
AU2025204845A1 (en) 2025-07-31
CA3211456A1 (en) 2022-09-09
JP2025186248A (ja) 2025-12-23
US20240132844A1 (en) 2024-04-25
KR20230137392A (ko) 2023-10-04

Similar Documents

Publication Publication Date Title
US20230000919A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
TWI799402B (zh) 產生腫瘤浸潤淋巴球的方法及其在免疫治療中的應用
JP7792426B2 (ja) 極めて強力なｍ－ｃｅｎｋ細胞及び方法
JP2015012876A (ja) 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
CN107002039A (zh) 使用t细胞用于培养自然杀伤细胞的方法
CN111918963A (zh) 表达趋化因子受体和细胞粘附分子的cd3阴性细胞群体及其用途和制备方法
TWI757785B (zh) 細胞激素誘導記憶型自然殺手細胞及其方法
JP2022540267A (ja) Ｃｉｍｌ ｎｋ細胞及びそれについての方法
TWI757709B (zh) 含有nk細胞之細胞集團之製造方法
US20220184122A1 (en) A method for providing immune cells
CN117120596A (zh) 高效的m-cenk细胞和方法
EP4574970A1 (en) Population of myeloid-derived suppressor cells and uses thereof
WO2025167821A1 (zh) 一种免疫细胞的培养方法和应用
JP2023153286A (ja) Ｎｋ細胞を含む細胞集団の製造方法
Lee Engineering Human Gamma Delta T Cells For Cancer Immunotherapy
WO2020152661A1 (ja) Ｎｋ細胞を含む細胞集団の製造方法
HK1240085B (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
HK1240085A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
HK1240616A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251215

R150 Certificate of patent or registration of utility model

Ref document number: 7792426

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150